and is being studied in NASH with advanced fibrosis (scarring) and cirrhosis. LJN452 is Novartis’ most advanced of two Farnesoid X receptor (FXR) agonists. Other companies such as Intercept ...
Novartis has joined with Allergan in a bid to get ahead in the race to get a drug approved to treat the fatty liver disease, non-alcoholic steatohepatitis (NASH). The Swiss pharma said it is to ...
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), are major health concerns. According to the American Liver Foundation, about 25% of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback